841 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by YHB Investment Advisors Inc.

YHB Investment Advisors Inc. purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 841 shares of the pharmaceutical company's stock, valued at approximately $339,000.

A number of other large investors have also bought and sold shares of VRTX. Edgewood Management LLC boosted its position in shares of Vertex Pharmaceuticals by 7,876.3% during the third quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company's stock worth $719,186,000 after purchasing an additional 1,526,983 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Vertex Pharmaceuticals by 18.1% during the 3rd quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company's stock worth $2,581,373,000 after purchasing an additional 851,054 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Vertex Pharmaceuticals by 17.2% in the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company's stock valued at $2,231,858,000 after purchasing an additional 704,421 shares during the period. Assenagon Asset Management S.A. boosted its stake in Vertex Pharmaceuticals by 169.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 839,672 shares of the pharmaceutical company's stock valued at $338,136,000 after purchasing an additional 528,029 shares during the period. Finally, International Assets Investment Management LLC grew its position in shares of Vertex Pharmaceuticals by 74,015.5% during the 3rd quarter. International Assets Investment Management LLC now owns 324,626 shares of the pharmaceutical company's stock worth $150,977,000 after purchasing an additional 324,188 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX traded up $0.84 during midday trading on Wednesday, reaching $441.52. 1,025,800 shares of the company's stock were exchanged, compared to its average volume of 1,495,690. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The company's 50 day simple moving average is $434.75 and its two-hundred day simple moving average is $463.64. The firm has a market capitalization of $113.70 billion, a PE ratio of -221.87, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the prior year, the firm earned $3.67 earnings per share. The firm's revenue was up 11.6% compared to the same quarter last year. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on VRTX. Piper Sandler cut their target price on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating on the stock in a research report on Monday. Raymond James reaffirmed a "market perform" rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. William Blair reiterated an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Monday, January 13th. Oppenheimer lowered shares of Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Thursday, December 19th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $494.76.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.